Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Turrini

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Cancer Biomarkers : Section a of Disease Markers|October 18, 2017
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatmentAlessandra Trojani, Ester Pungolino, Giuseppe Rossi, et al.
American Journal of Hematology|April 11, 2018
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemiaEster Pungolino, Giuseppe Rossi, Gabriella De Canal, et al.
Leukemia & Lymphoma|March 8, 2025
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ studyAlessandra Tucci, Alessandro Re, Chiara Pagani, et al.
American Journal of Hematology|December 11, 2024
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical TrialRoberto Cairoli, Arianna Gatti, Giovanni Grillo, et al.
Journal of Clinical Medicine|August 27, 2021
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in ItalyAlessandro Maria Vannucchi, Andrea Mortara, Andrea D'Alessio, et al.
Plos One|July 19, 2019
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatmentAlessandra Trojani, Ester Pungolino, Alessandra Dal Molin, et al.
European Journal of Human Genetics : EJHG|June 13, 2019
Searching for secondary findings: considering actionability and preserving the right not to knowBertrand Isidor, Sophie Julia, Pascale Saugier-Veber, et al.
Advances in Hematology|February 7, 2022
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb StudyMario Petrini, Gianluca Gaidano, Andrea Mengarelli, et al.
Cancer|August 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experienceRoberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, et al.
Cancers|May 14, 2025
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and CaregiversElena Crisà, Daniela Cilloni, Marta Riva, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancer Biomarkers : Section a of Disease Markers|October 18, 2017
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatmentAlessandra Trojani, Ester Pungolino, Giuseppe Rossi, et al.
American Journal of Hematology|April 11, 2018
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemiaEster Pungolino, Giuseppe Rossi, Gabriella De Canal, et al.
Leukemia & Lymphoma|March 8, 2025
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ studyAlessandra Tucci, Alessandro Re, Chiara Pagani, et al.
American Journal of Hematology|December 11, 2024
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical TrialRoberto Cairoli, Arianna Gatti, Giovanni Grillo, et al.
Journal of Clinical Medicine|August 27, 2021
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in ItalyAlessandro Maria Vannucchi, Andrea Mortara, Andrea D'Alessio, et al.
Plos One|July 19, 2019
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatmentAlessandra Trojani, Ester Pungolino, Alessandra Dal Molin, et al.
European Journal of Human Genetics : EJHG|June 13, 2019
Searching for secondary findings: considering actionability and preserving the right not to knowBertrand Isidor, Sophie Julia, Pascale Saugier-Veber, et al.
Advances in Hematology|February 7, 2022
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb StudyMario Petrini, Gianluca Gaidano, Andrea Mengarelli, et al.
Cancer|August 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experienceRoberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, et al.
Cancers|May 14, 2025
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and CaregiversElena Crisà, Daniela Cilloni, Marta Riva, et al.
Pageof 6